WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525690
CAS#: 1339058-04-6
Description: YL-0919 is a novel 5-HT1A receptor agonist and selective serotonin reuptake inhibitor.
Hodoodo Cat#: H525690
Name: YL-0919
CAS#: 1339058-04-6
Chemical Formula: C18H23ClN2O2
Exact Mass: 334.14
Molecular Weight: 334.844
Elemental Analysis: C, 64.57; H, 6.92; Cl, 10.59; N, 8.37; O, 9.56
Synonym: YL-0919, YL 0919, YL0919
IUPAC/Chemical Name: 1-(1-Benzyl-4-hydroxy-piperidin-4-ylmethyl)-1H-pyridin-2-one Hydrochloride
InChi Key: OXILSFMNCPZGAH-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H22N2O2.ClH/c21-17-8-4-5-11-20(17)15-18(22)9-12-19(13-10-18)14-16-6-2-1-3-7-16;/h1-8,11,22H,9-10,12-15H2;1H
SMILES Code: O=C1C=CC=CN1CC2(O)CCN(CC3=CC=CC=C3)CC2.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 334.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhang LM, Wang XY, Zhao N, Wang YL, Hu XX, Ran YH, Liu YQ, Zhang YZ, Yang RF, Li YF. Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT(1A) agonist. Br J Pharmacol. 2017 May;174(9):769-780. doi: 10.1111/bph.13675. Epub 2017 Mar 21. PubMed PMID: 27882537; PubMed Central PMCID: PMC5386994.
2: Qin JJ, Chen HX, Zhao N, Yuan L, Zhang YZ, Yang RF, Zhang LM, Li YF. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor. Neurosci Lett. 2014 Oct 17;582:104-8. doi: 10.1016/j.neulet.2014.09.009. Epub 2014 Sep 8. PubMed PMID: 25220701.
3: Chen HX, Jin ZL, Zhang LM, Xue R, Xu XD, Zhao N, Qiu ZK, Wang XW, Zhang YZ, Yang RF, Li YF. Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist. PLoS One. 2013 Dec 18;8(12):e83271. doi: 10.1371/journal.pone.0083271. eCollection 2013. PubMed PMID: 24367588; PubMed Central PMCID: PMC3867442.
